Status:

COMPLETED

Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth

Lead Sponsor:

GlaxoSmithKline

Conditions:

Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Eligibility:

All Genders

4-10 years

Phase:

PHASE3

Brief Summary

This study will only include infants born to mothers who are tested as seronegative for human immunodeficiency virus (HIV) \& hepatitis B surface antigen (HBsAg). The purpose of this study is to demon...

Detailed Description

Randomized study with two groups to receive one of the following vaccination regimens: * GSK Biologicals' Tritanrix™-HepB/Hib-MenAC * GSK Biologicals' Tritanrix™-HepB/Hiberix™

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Healthy infants aged 7 days +/- 3 days old born to mothers who are tested as seronegative for HIV \& HBsAg, written informed consent obtained from the parents, born after a gestation period of 36 to 42 weeks.
  • Exclusion criteria:
  • Known exposure to diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and/or meningococcal disease since birth.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on physical examination.
  • A family history of congenital or hereditary immunodeficiency.
  • Major congenital defects or serious illness.
  • Any neurologic disorders or seizures.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • A birth dose of hepatitis B vaccine given outside the frame of this study.

Exclusion

    Key Trial Info

    Start Date :

    October 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 1 2005

    Estimated Enrollment :

    192 Patients enrolled

    Trial Details

    Trial ID

    NCT00317122

    Start Date

    October 1 2004

    End Date

    July 1 2005

    Last Update

    September 21 2016

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    GSK Investigational Site

    Brits, South Africa, 0250

    2

    GSK Investigational Site

    Brits, South Africa

    3

    GSK Investigational Site

    Centurion, South Africa

    4

    GSK Investigational Site

    Ga-Rankuwa, South Africa, 0208